首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1797940

全球多組體學市場：未來預測（至 2032 年）—按類型、產品/服務、技術、應用、最終用戶和地區進行分析

Multiomics Market Forecasts to 2032 - Global Analysis By Type, Product & Service, Technology, Application, End User and By Geography

出版日期: 2025年08月07日 | 出版商:

Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，全球多組體學市場預計在 2025 年達到 32 億美元，到 2032 年將達到 91 億美元，預測期內的複合年成長率為 15.9%。

多體學是對多個「體學」資料集（包括基因組學、蛋白質組學、轉錄組學和代謝體學）的整合分析，以全面了解生物系統。透過聚合不同的分子層，多組體學能夠實現準確的疾病分析、生物標記發現和標靶治療的開發。多組體學增強了精準醫療、診斷和藥物開發等領域的數據主導決策。

精準醫療和個人化治療的興起

多體學透過整合基因組學、轉錄組學、蛋白質組學和代謝組學數據，創建詳細的患者檔案，提供實現此類個人化治療所需的全面分子洞察。這種綜合分析使醫療專業人員能夠識別特定的疾病機制，預測治療反應，並制定有針對性的治療性介入。此外，癌症、糖尿病和心血管疾病等慢性疾病的日益流行，推動了對個人化治療解決方案的需求，並促使公共和私營部門在多體學研發方面投入大量資金。

缺乏標準化的分析流程

缺乏標準化的資料整合和解讀框架仍然是多體學市場面臨的一大挑戰，這限制了研究成果的傳播和可重複性。各種體學資料集的格式和結構各不相同，使得無縫整合對研究人員來說極為複雜且耗時。此外，開發用於多組體學分析的穩健計算流程的複雜性，加上專用設備和高技能人員的高昂成本，給小型研究機構帶來了巨大的障礙，並限制了市場滲透。

人工智慧/機器學習在多組體學資料分析中的整合

人工智慧演算法擅長整合和分析來自不同體學學科的大量資料集，從而能夠更快地識別疾病亞型、藥物標靶和生物標記物，加速藥物研發進程。雲端處理平台正在改變研究人員處理大型複雜多組體學資料集的方式，提供可擴展且經濟高效的資料儲存和分析解決方案。先進的人工智慧預測模型可以識別特定疾病的風險個體並預測治療反應，促進更有效的個人化治療方案的開發，並提高多種醫療應用的診斷準確性。

資料外洩和網路安全事件的風險

歐盟的《一般資料保護規範》（GDPR）和美國的《健康保險流通與責任法案》（HIPAA）等嚴格的監管要求，對個人基因組和分子資料的收集、儲存和共用提出了複雜的合規義務。隨著研究網路和雲端基礎平台的互聯程度日益加深，潛在網路威脅的攻擊面也隨之擴大。涉及多組體學資訊的資料外洩可能會造成深遠的後果，包括身分盜竊、歧視以及病患信任的喪失。

COVID-19的影響：

COVID-19疫情顯著加速了多體學的研究和應用，彰顯了該技術在理解病毒病原體和宿主免疫反應方面的關鍵作用。調查團隊採用整合的多組學體學，對COVID-19患者的血漿蛋白、代謝物和細胞轉錄物進行了分析，揭示了單體學方法無法捕捉的全面分子圖譜。這些研究確定了84種可用於治療COVID-19的潛在化合物，並透過計算分析發現了6種候選藥物。此外，這次疫情凸顯了多體學在偵測病毒入侵途徑和補體系統活化方面的卓越能力，為治療性介入策略提供了重要見解。

預計批量多組體學細分市場將成為預測期內最大的細分市場

由於批量多體學學在大規模人口研究、藥物研發項目和綜合疾病分析應用中的廣泛應用，預計在預測期內將佔據最大的市場佔有率。由於與單細胞方法相比，批量多組學具有成本效益，並且具有成熟的分析工具和通訊協定，因此該方法仍然是多體學工作流程中的標準方法。此外，研究機構和製藥公司更傾向於使用批量多組體學進行廣泛的基因組研究和生物標記發現項目，因為它能夠為不同的患者群體提供可靠的結果。

精準醫療預計將在預測期內達到最高複合年成長率

精準醫療領域預計將在預測期內呈現最高成長率。這得益於多體學數據的獨特能力，它能夠根據每位患者的分子特徵量身定做治療方案，從而實現更有效、更個性化的醫療結果。該方法結合基因組學、蛋白質組學、代謝體學和其他層面的分子數據，以分析疾病的根本原因並預測患者對不同治療的反應，從而加深對疾病機制的理解並確定具體的治療標靶。此外，人們日益認知到，傳統的「一刀切」治療方法不足以應對複雜疾病，這也推動了精準醫療的投資和研究。

佔比最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其強大的科研基礎設施、對醫療和生物技術研發的大量投資，以及政府和私營部門資助計劃的大力支持。該地區擁有賽默飛世爾科技、Illumina、安捷倫科技和凱傑等領先的生命科學公司，推動多組體學方法和技術的持續創新。美國食品藥物管理局 (FDA) 對基於生物標記的藥物開發的支持性法規環境，加上該地區先進的醫療保健基礎設施和對個人化醫療的重視，增強了北美的優勢。

複合年成長率最高的地區：

預計亞太地區在預測期內將呈現最高的複合年成長率，這得益於生命科學研究投資的增加、生物技術新興企業的快速擴張以及醫療保健基礎設施的顯著改善，尤其是在中國、日本和印度等主要市場。該全部區域的舉措正透過印度國家發展計畫和永續目標等綜合政策積極推動生物技術的發展，這些政策特別支持生物技術發展和生物製造能力。此外，該地區各種疾病的日益普及推動了人們對新型藥物發現應用的更多關注，而中國等國家正透過華大基因集團等公司成為多組體學研究的領導者，大力投資基因組學研究和精準醫療計劃。支持性的法規環境、不斷成長的醫療保健意識以及政府的戰略支持，使亞太地區成為成長最快的區域市場。

產品和服務

裝置
耗材
軟體和分析平台
服務

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

公司簡介
- 對最多三家其他公司進行全面分析
- 主要企業的SWOT分析（最多3家公司）
區域分類
- 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
競爭基準化分析
- 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲國家
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他亞太地區
南美洲
- 阿根廷
- 巴西
- 智利
- 南美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲地區

第11章：主要趨勢

合約、商業夥伴關係和合資企業
企業合併與收購（M&A）
新產品發布
業務擴展
其他關鍵策略

第12章公司概況

10x Genomics
Agilent Technologies
Becton, Dickinson and Company（BD）
BGI Genomics
Bio-Rad Laboratories
Bio-Techne Corporation
Bruker
Danaher Corporation
Illumina
Mission Bio
NanoString Technologies
Oxford Nanopore Technologies
Pacific Biosciences（PacBio）
Revvity
QIAGEN
Roche
Standard BioTools
Shimadzu Corporation
Thermo Fisher Scientific
Human Longevity, Inc.

簡介目錄圖表

Product Code: SMRC30310

According to Stratistics MRC, the Global Multiomics Market is accounted for $3.2 billion in 2025 and is expected to reach $9.1 billion by 2032 growing at a CAGR of 15.9% during the forecast period. Multiomics is the integrated analysis of multiple "omics" data sets genomics, proteomics, transcriptomics, metabolomics, and more to gain a comprehensive understanding of biological systems. By aggregating diverse molecular layers, multiomics enables precise disease profiling, biomarker discovery, and targeted therapeutic development. It enhances data-driven decision-making across sectors such as precision medicine, diagnostics, and drug development.

Market Dynamics:

Driver:

Rise in precision medicine & personalized therapies

Multiomics provides the comprehensive molecular insights necessary to enable this personalized approach by integrating genomic, transcriptomic, proteomic, and metabolomic data to create detailed patient profiles. This integrated analysis allows healthcare professionals to identify specific disease mechanisms, predict treatment responses, and develop targeted therapeutic interventions. Furthermore, the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions has intensified the demand for personalized treatment solutions, driving significant investments from both private and public sectors in multiomics research and development.

Restraint:

Lack of standardized analytical pipelines

The absence of standardized frameworks for data integration and interpretation continues to pose significant challenges for the multiomics market, limiting widespread adoption and reproducibility of research findings. Different omics datasets possess varying formats and structures, making seamless integration extremely complex and time-consuming for researchers. Additionally, the complexity of developing robust computational pipelines for multiomics analysis, combined with the high costs associated with specialized equipment and highly skilled personnel, creates substantial barriers for smaller research organizations and limits market penetration.

Opportunity:

Integration of AI/ML in multiomics data analysis

AI algorithms excel at integrating and analyzing vast datasets from various omics fields, enabling faster identification of disease subtypes, drug targets, and biomarkers while accelerating drug discovery processes. Cloud computing platforms are transforming how researchers handle large and complex multiomics datasets, providing scalable and cost-effective solutions for data storage and analysis. Advanced AI-driven predictive models can identify individuals at risk for specific diseases and predict treatment responses, facilitating the development of more effective personalized therapies and improving diagnostic accuracy across multiple healthcare applications.

Threat:

Risk of data breach or cybersecurity incidents

Stringent regulatory requirements such as GDPR in the European Union and HIPAA in the United States impose complex compliance obligations for collecting, storing, and sharing personal genomic and molecular data. The increasing interconnectedness of research networks and cloud-based platforms expands the attack surface for potential cyber threats. Data breaches involving multiomics information could have far-reaching consequences, including identity theft, discrimination, and loss of patient trust.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated multiomics research and applications, demonstrating the technology's critical role in understanding viral pathogenesis and host immune responses. Researchers utilized integrated multiomics approaches to profile plasma proteins, metabolites, and cellular transcripts from COVID-19 patients, revealing comprehensive molecular landscapes that single omics approaches could not capture. These studies identified 84 potentially active compounds for COVID-19 treatment and led to the discovery of six candidate drugs through computational analysis. Additionally, the pandemic highlighted multiomics' superior ability to detect viral entry pathways and complement system activation, providing crucial insights for therapeutic intervention strategies.

The bulk multiomics segment is expected to be the largest during the forecast period

The bulk multiomics segment is expected to account for the largest market share during the forecast period due to its widespread adoption in large-scale population studies, drug discovery initiatives, and comprehensive disease profiling applications. This approach remains the standard in multiomics workflows because of its cost-effectiveness compared to single-cell alternatives and the availability of well-established analytical tools and protocols. Additionally, research institutions and pharmaceutical companies prefer bulk multiomics for conducting extensive genomic studies and biomarker discovery programs, as it provides reliable results across diverse patient populations.

The precision medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the precision medicine segment is predicted to witness the highest growth rate, driven by multiomics data's unique ability to customize treatments based on individual patient molecular characteristics, resulting in more effective and personalized healthcare outcomes. This approach combines genomics, proteomics, metabolomics, and other molecular data layers to provide deeper understanding of disease mechanisms and identify specific therapeutic targets by analyzing root causes of diseases and predicting patient responses to different treatments. Furthermore, the growing recognition that traditional one-size-fits-all treatment approaches are inadequate for complex diseases continues to drive investment and research.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its robust research infrastructure, substantial investments in healthcare and biotechnology R&D, and strong support from both government and private sector funding initiatives. The region benefits from the presence of major life science companies, including Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which drive continuous innovation in multiomics approaches and technologies. The FDA's supportive regulatory environment for biomarker-guided drug development, combined with the region's advanced healthcare infrastructure and focus on personalized medicine, reinforces North America's dominant position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by increasing investments in life sciences research, a rapidly expanding number of biotechnology startups, and substantial improvements in healthcare infrastructure, particularly in key markets like China, Japan, and India. Government initiatives across the region actively promote biotechnology growth through comprehensive policies such as India's National Development Programmes and Sustainable Development Goals, which specifically support biotech development and biomanufacturing capabilities. Moreover, the region's growing prevalence of various diseases has intensified focus on novel drug discovery applications, with countries like China emerging as leaders in multiomics research through companies like BGI Group and substantial investments in genomics research and precision medicine initiatives. The combination of supportive regulatory environments, increasing healthcare awareness, and strategic government backing positions Asia Pacific as the fastest-growing regional market

Key players in the market

Some of the key players in Multiomics Market include 10x Genomics, Agilent Technologies, Becton, Dickinson and Company (BD), BGI Genomics, Bio-Rad Laboratories, Bio-Techne Corporation, Bruker, Danaher Corporation, Illumina, Mission Bio, NanoString Technologies, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), Revvity, QIAGEN, Roche, Standard BioTools, Shimadzu Corporation, Thermo Fisher Scientific, and Human Longevity, Inc.

Key Developments:

In June 2025, Illumina, Inc. announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

In August 2024, Agilent announced a cooperation agreement with Sangon Biotech to advance nucleic acid research, with particular focus on promoting development in synthetic biology and multi-omics.

In January 2024, BD announced collaboration with Hamilton to develop automated applications and robotics-compatible reagent kits to enable greater standardization in large-scale single-cell multiomics experiments.

Types Covered:

Genomics
Transcriptomics
Proteomics
Metabolomics
Epigenomics
Lipidomics
Microbiomics

Product & Services:

Instruments
Consumables
Software & Analytics Platforms
Services

Technologies Covered:

Single-Cell Multiomics
Bulk Multiomics
Spatial Multiomics

Applications Covered:

Drug Discovery & Development
Precision Medicine
Biomarker Discovery
Clinical Diagnostics
Agrigenomics
Personalized Nutrition
Environmental Research
Microbiome Analysis
Other Applications

End Users Covered:

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Clinics
CROs & CDMOs
Diagnostic Laboratories
Agrigenomics Companies
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Multiomics Market, By Type

5.1 Introduction
5.2 Genomics
5.3 Transcriptomics
5.4 Proteomics
5.5 Metabolomics
5.6 Epigenomics
5.7 Lipidomics
5.8 Microbiomics

6 Global Multiomics Market, By Product & Service

6.1 Introduction
6.2 Instruments
- 6.2.1 Sequencing Instruments
- 6.2.2 Mass Spectrometers
- 6.2.3 Chromatography Systems
- 6.2.4 Microarrays
6.3 Consumables
- 6.3.1 Reagents & Kits
- 6.3.2 Assay Kits
- 6.3.3 Sample Preparation Kits
6.4 Software & Analytics Platforms
- 6.4.1 Data Integration & Visualization Tools
- 6.4.2 AI/ML Platforms
6.5 Services
- 6.5.1 Multiomics Data Analysis
- 6.5.2 Custom Services
- 6.5.3 Contract Research Services

7 Global Multiomics Market, By Technology

7.1 Introduction
7.2 Single-Cell Multiomics
7.3 Bulk Multiomics
7.4 Spatial Multiomics

8 Global Multiomics Market, By Application

8.1 Introduction
8.2 Drug Discovery & Development
8.3 Precision Medicine
8.4 Biomarker Discovery
8.5 Clinical Diagnostics
8.6 Agrigenomics
8.7 Personalized Nutrition
8.8 Environmental Research
8.9 Microbiome Analysis
8.10 Other Applications

9 Global Multiomics Market, By End User

9.1 Introduction
9.2 Pharmaceutical & Biotechnology Companies
9.3 Academic & Research Institutes
9.4 Hospitals & Clinics
9.5 CROs & CDMOs
9.6 Diagnostic Laboratories
9.7 Agrigenomics Companies
9.8 Other End Users

10 Global Multiomics Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 10x Genomics
12.2 Agilent Technologies
12.3 Becton, Dickinson and Company (BD)
12.4 BGI Genomics
12.5 Bio-Rad Laboratories
12.6 Bio-Techne Corporation
12.7 Bruker
12.8 Danaher Corporation
12.9 Illumina
12.10 Mission Bio
12.11 NanoString Technologies
12.12 Oxford Nanopore Technologies
12.13 Pacific Biosciences (PacBio)
12.14 Revvity
12.15 QIAGEN
12.16 Roche
12.17 Standard BioTools
12.18 Shimadzu Corporation
12.19 Thermo Fisher Scientific
12.20 Human Longevity, Inc.

簡介目錄圖表

List of Tables

Table 1 Global Multiomics Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Multiomics Market Outlook, By Type (2024-2032) ($MN)
Table 3 Global Multiomics Market Outlook, By Genomics (2024-2032) ($MN)
Table 4 Global Multiomics Market Outlook, By Transcriptomics (2024-2032) ($MN)
Table 5 Global Multiomics Market Outlook, By Proteomics (2024-2032) ($MN)
Table 6 Global Multiomics Market Outlook, By Metabolomics (2024-2032) ($MN)
Table 7 Global Multiomics Market Outlook, By Epigenomics (2024-2032) ($MN)
Table 8 Global Multiomics Market Outlook, By Lipidomics (2024-2032) ($MN)
Table 9 Global Multiomics Market Outlook, By Microbiomics (2024-2032) ($MN)
Table 10 Global Multiomics Market Outlook, By Product & Service (2024-2032) ($MN)
Table 11 Global Multiomics Market Outlook, By Instruments (2024-2032) ($MN)
Table 12 Global Multiomics Market Outlook, By Sequencing Instruments (2024-2032) ($MN)
Table 13 Global Multiomics Market Outlook, By Mass Spectrometers (2024-2032) ($MN)
Table 14 Global Multiomics Market Outlook, By Chromatography Systems (2024-2032) ($MN)
Table 15 Global Multiomics Market Outlook, By Microarrays (2024-2032) ($MN)
Table 16 Global Multiomics Market Outlook, By Consumables (2024-2032) ($MN)
Table 17 Global Multiomics Market Outlook, By Reagents & Kits (2024-2032) ($MN)
Table 18 Global Multiomics Market Outlook, By Assay Kits (2024-2032) ($MN)
Table 19 Global Multiomics Market Outlook, By Sample Preparation Kits (2024-2032) ($MN)
Table 20 Global Multiomics Market Outlook, By Software & Analytics Platforms (2024-2032) ($MN)
Table 21 Global Multiomics Market Outlook, By Data Integration & Visualization Tools (2024-2032) ($MN)
Table 22 Global Multiomics Market Outlook, By AI/ML Platforms (2024-2032) ($MN)
Table 23 Global Multiomics Market Outlook, By Services (2024-2032) ($MN)
Table 24 Global Multiomics Market Outlook, By Multiomics Data Analysis (2024-2032) ($MN)
Table 25 Global Multiomics Market Outlook, By Custom Services (2024-2032) ($MN)
Table 26 Global Multiomics Market Outlook, By Contract Research Services (2024-2032) ($MN)
Table 27 Global Multiomics Market Outlook, By Technology (2024-2032) ($MN)
Table 28 Global Multiomics Market Outlook, By Single-Cell Multiomics (2024-2032) ($MN)
Table 29 Global Multiomics Market Outlook, By Bulk Multiomics (2024-2032) ($MN)
Table 30 Global Multiomics Market Outlook, By Spatial Multiomics (2024-2032) ($MN)
Table 31 Global Multiomics Market Outlook, By Application (2024-2032) ($MN)
Table 32 Global Multiomics Market Outlook, By Drug Discovery & Development (2024-2032) ($MN)
Table 33 Global Multiomics Market Outlook, By Precision Medicine (2024-2032) ($MN)
Table 34 Global Multiomics Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
Table 35 Global Multiomics Market Outlook, By Clinical Diagnostics (2024-2032) ($MN)
Table 36 Global Multiomics Market Outlook, By Agrigenomics (2024-2032) ($MN)
Table 37 Global Multiomics Market Outlook, By Personalized Nutrition (2024-2032) ($MN)
Table 38 Global Multiomics Market Outlook, By Environmental Research (2024-2032) ($MN)
Table 39 Global Multiomics Market Outlook, By Microbiome Analysis (2024-2032) ($MN)
Table 40 Global Multiomics Market Outlook, By Other Applications (2024-2032) ($MN)
Table 41 Global Multiomics Market Outlook, By End User (2024-2032) ($MN)
Table 42 Global Multiomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
Table 43 Global Multiomics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
Table 44 Global Multiomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
Table 45 Global Multiomics Market Outlook, By CROs & CDMOs (2024-2032) ($MN)
Table 46 Global Multiomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
Table 47 Global Multiomics Market Outlook, By Agrigenomics Companies (2024-2032) ($MN)
Table 48 Global Multiomics Market Outlook, By Other End Users (2024-2032) ($MN)